WO2012012391A2 - Process for preparing pyrano - [2,3-c]pyridine derivatives - Google Patents
Process for preparing pyrano - [2,3-c]pyridine derivatives Download PDFInfo
- Publication number
- WO2012012391A2 WO2012012391A2 PCT/US2011/044489 US2011044489W WO2012012391A2 WO 2012012391 A2 WO2012012391 A2 WO 2012012391A2 US 2011044489 W US2011044489 W US 2011044489W WO 2012012391 A2 WO2012012391 A2 WO 2012012391A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- formula
- reagent
- dehydrating
- Prior art date
Links
- BVIHAADUZBOGSJ-UHFFFAOYSA-N 2h-pyrano[2,3-c]pyridine Chemical class N1=CC=C2C=CCOC2=C1 BVIHAADUZBOGSJ-UHFFFAOYSA-N 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 72
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 230000001590 oxidative effect Effects 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 150000007530 organic bases Chemical class 0.000 claims description 7
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical group CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 claims description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 claims description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 6
- 239000012448 Lithium borohydride Substances 0.000 claims description 5
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 claims description 5
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910010084 LiAlH4 Inorganic materials 0.000 claims description 3
- 238000006859 Swern oxidation reaction Methods 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract description 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- 239000000203 mixture Substances 0.000 description 41
- 238000003756 stirring Methods 0.000 description 19
- 239000010410 layer Substances 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012455 biphasic mixture Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- -1 w-propyl Chemical group 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QXVCUSYHDODUGS-UHFFFAOYSA-N 3,4-dihydro-2h-pyrano[2,3-c]pyridin-6-ylmethanol Chemical compound C1CCOC2=C1C=C(CO)N=C2 QXVCUSYHDODUGS-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- BJRREYNGXNOFPY-UHFFFAOYSA-N methyl 2-oxo-2-[(2-oxo-2-pent-4-enoxyethyl)amino]acetate Chemical compound COC(=O)C(=O)NCC(=O)OCCCC=C BJRREYNGXNOFPY-UHFFFAOYSA-N 0.000 description 3
- QZRHDMKYWOXBLB-UHFFFAOYSA-N pent-4-enyl 2-[(2-ethoxy-2-oxoacetyl)amino]-2-phenylacetate Chemical compound C=CCCCOC(=O)C(NC(=O)C(=O)OCC)C1=CC=CC=C1 QZRHDMKYWOXBLB-UHFFFAOYSA-N 0.000 description 3
- MVLWTBBHPRPPOX-UHFFFAOYSA-N pent-4-enyl 2-[(2-ethoxy-2-oxoacetyl)amino]propanoate Chemical compound CCOC(=O)C(=O)NC(C)C(=O)OCCCC=C MVLWTBBHPRPPOX-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- DSOLBHZRAGNEPO-UHFFFAOYSA-N 3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carbaldehyde Chemical compound C1CCOC2=C1C=C(C=O)N=C2 DSOLBHZRAGNEPO-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- MIYJIDZRMVVQCP-UHFFFAOYSA-N methyl 3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carboxylate Chemical compound C1CCOC2=C1C=C(C(=O)OC)N=C2 MIYJIDZRMVVQCP-UHFFFAOYSA-N 0.000 description 2
- LQAVWYMTUMSFBE-UHFFFAOYSA-N pent-4-en-1-ol Chemical compound OCCCC=C LQAVWYMTUMSFBE-UHFFFAOYSA-N 0.000 description 2
- UOKJRXXHZJOPAL-UHFFFAOYSA-N pent-4-enyl 2-[(2-ethoxy-2-oxoacetyl)amino]-3-phenylpropanoate Chemical compound C=CCCCOC(=O)C(NC(=O)C(=O)OCC)CC1=CC=CC=C1 UOKJRXXHZJOPAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- WTQJVYWOYHZLSP-UHFFFAOYSA-N 2h-pyrano[2,3-c]pyridine-6-carbaldehyde Chemical compound C1=CCOC2=C1C=C(C=O)N=C2 WTQJVYWOYHZLSP-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- VTIODUHBZHNXFP-NSCUHMNNSA-N 4-Hexen-1-ol, (E)- Chemical compound C\C=C\CCCO VTIODUHBZHNXFP-NSCUHMNNSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IGIPRDHXEPLCFT-UHFFFAOYSA-N ethyl 2,3,4,5-tetrahydrooxepino[2,3-c]pyridine-7-carboxylate Chemical compound C1CCCOC2=C1C=C(C(=O)OCC)N=C2 IGIPRDHXEPLCFT-UHFFFAOYSA-N 0.000 description 1
- FKZCJUZAVSQWNQ-UHFFFAOYSA-N ethyl 2-[(2-hex-5-enoxy-2-oxoethyl)amino]-2-oxoacetate Chemical compound CCOC(=O)C(=O)NCC(=O)OCCCCC=C FKZCJUZAVSQWNQ-UHFFFAOYSA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- IDLNDVZFBKVVSL-UHFFFAOYSA-N ethyl 5-methyl-3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carboxylate Chemical compound O1CCCC2=C(C)C(C(=O)OCC)=NC=C21 IDLNDVZFBKVVSL-UHFFFAOYSA-N 0.000 description 1
- WMAYYLMRRFSMFO-UHFFFAOYSA-N ethyl 8-benzyl-3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carboxylate Chemical compound N=1C(C(=O)OCC)=CC=2CCCOC=2C=1CC1=CC=CC=C1 WMAYYLMRRFSMFO-UHFFFAOYSA-N 0.000 description 1
- DETIBGSHGAPUKI-UHFFFAOYSA-N ethyl 8-methyl-3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carboxylate Chemical compound C1CCOC2=C1C=C(C(=O)OCC)N=C2C DETIBGSHGAPUKI-UHFFFAOYSA-N 0.000 description 1
- PGZDIXARNADHDQ-UHFFFAOYSA-N ethyl 8-phenyl-3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carboxylate Chemical compound N=1C(C(=O)OCC)=CC=2CCCOC=2C=1C1=CC=CC=C1 PGZDIXARNADHDQ-UHFFFAOYSA-N 0.000 description 1
- UIZVMOZAXAMASY-UHFFFAOYSA-N hex-5-en-1-ol Chemical compound OCCCCC=C UIZVMOZAXAMASY-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 1
- HZOMNCROTGWGJK-UHFFFAOYSA-N methyl 5-methyl-3,4-dihydro-2h-pyrano[2,3-c]pyridine-6-carboxylate Chemical compound O1CCCC2=C(C)C(C(=O)OC)=NC=C21 HZOMNCROTGWGJK-UHFFFAOYSA-N 0.000 description 1
- FSUXYWPILZJGCC-UHFFFAOYSA-N pent-4-en-1-ol Natural products CC=CCCO FSUXYWPILZJGCC-UHFFFAOYSA-N 0.000 description 1
- FAMWXTURFKINAG-UHFFFAOYSA-N pent-4-enyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate Chemical compound CC(C)(C)OC(=O)NCC(=O)OCCCC=C FAMWXTURFKINAG-UHFFFAOYSA-N 0.000 description 1
- AFJIFVVIVBBWIZ-UHFFFAOYSA-N pent-4-enyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)OCCCC=C AFJIFVVIVBBWIZ-UHFFFAOYSA-N 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the present invention relates to pyrano-[2,3-c]pyridine derivatives and methods for their preparation.
- 3,4-Dihydro-2H-pyrano[2,3-c]pyridine-6-carbaldehyde disclosed in WO2004058144, is characterized by the following Formula (VIII):
- Pyrano-[2,3-c]pyridine derivatives have shown promise as useful intermediates to compounds useful for treating bacterial infections.
- Previously disclosed methods for preparing pyrano-[2,3-c]pyridine-6-carbaldehyde are arduous, requiring many steps using expensive starting materials and resulting in unsatisfactory overall yields. (See
- the present invention is a process comprising dehydrating a compound of Formula (I):
- R 2 is Ci-C 4 -alkyl
- R 3 is H, Ci-C 4 -alkyl, benzyl, -phenyl-(R 10 ) x , or -Ci-C4-alkyl-COO-Ci-C 4 -alkyl;
- each R 4 is independently H, or Ci-C 4 -alkyl
- each R 5 and each R 6 are independently H, Ci-C 4 -alkyl, -0-Ci-C 4 -alkyl, or -S-Ci-C 4 -alkyl;
- R 7 is R 8 or -CH 2 -R 9 ;
- R 8 is H, Ci-C 4 -alkyl, -phenyl-(R 10 ) x , or -COO-Ci-C 4 -alkyl;
- R 9 is H, Ci-Cs-alkyl, -phenyl-(R 10 ) x , or -COO-Ci-C 4 -alkyl;
- each R 10 is independently halo, Ci-C 4 -alkyl, -0-Ci-C6-alkyl, or -S-Ci-C 4 -alkyl; and each x is independently 0, 1, or 2.
- the present invention is a process comprising the step of dehydrating a compound of Formula (V):
- R 2 is Ci-C 4 -alkyl.
- Compounds of Formula (II) have shown promise as intermediates to compounds useful for treating bacterial infections.
- the present invention is a process comprising dehydrating a compound of Formula (I):
- R x -R 7 are as previously defined.
- Ci-C4-alkyl is used herein to refer to a straight chain or branched alkyl group with up to four carbon atoms. Examples include methyl, ethyl, w-propyl, isopropyl, w-butyl, sec-butyl, and ?-butyl.
- Ci-C3-alkyl refers to methyl, ethyl, w-propyl, or isopropyl.
- R 4 , R 5 , and R 6 are each independently H or Ci-C4-alkyl.
- R 4 , R 5 , and R 6 are each independently H or methyl.
- each of R 4 , R 5 , and R 6 is H.
- dehydrating reagents examples include trifluoromethanesulfonic anhydride (Tf 2 0) and phosphorus pentoxide (P2O5), preferably Tf 2 0.
- the reaction of Compound (I) to Compound (II) [or Compound (V) to Compound (VI)] is advantageously carried out in the presence of a suitable base, preferably an organic base such as pyridine, triethylamine, or diisopropylethylamine.
- a suitable base preferably an organic base such as pyridine, triethylamine, or diisopropylethylamine.
- the base is used in a range of from 1 equivalent with respect to Compound (I) to less than the amount, in equivalents, of the dehydrating reagent.
- the compound of Formula (4) can be prepared by deprotecting a compound of Formula (3):
- a strong acid such as HC1, H 2 S0 4 , MsOH or TsOH.
- the compound of Formula (3) can be prepared by condensing a compound of Formula (1):
- condensation conditions for example, in the presence of 1, 1'- carbonyldiimidazole.
- Suitable reducing reagents include diisobutylaluminium hydride, LiAlH 4 , LiBH 4 , and NaBH 4 .
- the compound of Formula (III) can be contacted with a suitable oxidizing reag to form a compound of Formula (IV):
- Suitable oxidizing reagents include M11O 2 , Swern oxidation reagents, 2-iodoxybenzoic acid, pyridine sulphur trioxide, and Dess-Martin periodinane.
- Scheme 1 illustrates one aspect of the present invention.
- Compound (3) can be prepared by contacting acid (1) with alcohol (2) under suitable condensation conditions, for example, in the presence of 1 , 1 '-carbonyldiimidazole.
- the protecting group is removed from compound (3) to form amine (4) under suitable deprotecting conditions, preferably by reaction with a strong acid, such as HC1, H2SO4, MsOH or TsOH.
- the compound of Formula (Ila) can be prepared by treatment of the compound of Formula (la) with suitable base and dehydrating reagent, for example, pyridine and Tf 2 0.
- suitable base and dehydrating reagent for example, pyridine and Tf 2 0.
- the compound of Formula (IVa) can be prepared in at least two ways.
- the compound of Formula (Ila) can be reduced to alcohol (Ilia) using a suitable reducing reagent such as diisobutylaluminium hydride, LiAlH 4 , LiBH 4 , or NaBH 4 .
- Alcohol (Ilia) can then be oxidized to form the compound of Formula (IVa) using a suitable oxidizing reagent such as Mn0 2 , Swern oxidation reagents, 2-iodoxybenzoic acid, pyridine sulphur trioxide, or Dess-Martin periodinane.
- a suitable oxidizing reagent such as Mn0 2 , Swern oxidation reagents, 2-iodoxybenzoic acid, pyridine sulphur trioxide, or Dess-Martin periodinane.
- the compound of Formula (Ila) can be reduced to form the compound of Formula (IVa) using a suitable reducing reagent such as diisobutylaluminium hydride.
- Scheme 2 Another embodiment of the present invention is illustrated in Scheme 2.
- the compound of Formula (IVb) can be prepared in a similar manner as the compounds in Scheme 1 starting from alcohol (6).
- Methanesulfonic acid 34 g, 1.25 eq
- the mixture was stirred at 40 °C for 2 h then cooled to 20 °C.
- the mixture was then transferred into a vessel containing dimethyl oxalate (34 g, 1 eq) and the temperature of the vessel was maintained at 20 °C with stirring.
- Triethylamine 43 g, 1.5 eq was then added to this mixture stirring was continued for a further 1 h.
- the mixture was washed with water (125 mL).
- the aqueous layer was extracted with DCM (85 mL).
- the combined organic layers were washed first with water (127.5 mL) and 10 wt% citric acid solution (170 mL).
- 6N HC1 (127.5 mL) was added to the mixture to form a biphasic mixture.
- the two layers were separated and the organic layer was extracted with 6 N HC1 (85 mL).
- the acidic aqueous layers were combined and DCM (127.5 mL) was added. While maintaining the temperature below 25 °C, 28 wt% aqueous NH 4 OH was slowly added until the pH of the aqueous layer reached 3-5.
- the two layers were separated and the aqueous layer was extracted with DCM (85 mL).
- Pent-4-en- 1 -yl 2-(2-ethoxy-2-oxoacetamido)propanoate (1.05 g, 1 eq) and DCM (15 mL) were added to a vessel with stirring. Pyridine (0.39 g, 1.2 eq) was then added and the mixture was cooled to 15 °C. Tf 2 0 (1.7 g, 1.5 eq) was added to the mixture over 15 min and the mixture was warmed to ambient temperature to stir for 1.5 h. The reaction was quenched by the addition of DCM and 20 wt% aqueous NaOAc to form a biphasic mixture. The layers were separated and the organic layer was washed with water.
- Pent-4-en- 1 -yl 2-(2-ethoxy-2-oxoacetamido)-3-phenylpropanoate was prepared in a similar manner as Example 2(a) starting with N-(?-butoxycarbony ⁇ phenylalanine (1.0 g).
- the mixture was washed with 20 wt% aqueous NaOAc (2 x 1.5 mL), 10 wt% aqueous citric acid (3 x 1.5 mL), and water (1 x 1.5 mL). The organic layer was then concentrated under reduced pressure to provide the title compound as a solid.
- Ethyl-2-((2-(hex-5-en-l-yloxy)-2-oxoethyl)amino)-2-oxoacetate (0.35 g) and DCM (4 mL) were added to a vessel with stirring followed by the addition of pyridine (0.13 g). Tf 2 0 (0.58 g) was then added to the mixture slowly at ambient temperature. The mixture was stirred at ambient temperature for 4 days after which time the mixture was extracted with 6N HC1 (3 x 10 mL). The combined acid layers were washed with DCM (10 mL) and the pH was adjusted to -10 with solid K2CO 3 . The basic aqueous layer was extracted with DCM (20 mL).
- the mixture was stirred at ⁇ 0 to 7 °C for ⁇ 5 to 8 h then quenched with aqueous 5 wt% NaHCC solution (3 L) to form a biphasic mixture.
- the layers were separated and the aqueous layer was extracted with DCM (0.9 L).
- the combined organic layers were washed with aqueous 5 wt% citric acid (3.0 L) and brine (300 mL), dried over anhydrous sodium sulfate and filtered to provide the title compound in DCM solution.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11810260.7A EP2595994B1 (en) | 2010-07-20 | 2011-07-19 | Process for preparing pyrano - [2,3-c]pyridine derivatives |
CN201180035535.7A CN103492393A (en) | 2010-07-20 | 2011-07-19 | Process for preparing pyrano - [2,3-c]pyridine derivatives |
ES11810260.7T ES2574179T3 (en) | 2010-07-20 | 2011-07-19 | Procedure for preparing derivatives of pyrano- [2,3-c] pyridine |
US13/810,741 US8759523B2 (en) | 2010-07-20 | 2011-07-19 | Process for preparing pyrano—[2,3-C]pyridine derivatives |
BR112013001257A BR112013001257A2 (en) | 2010-07-20 | 2011-07-19 | process. |
JP2013520798A JP5762538B2 (en) | 2010-07-20 | 2011-07-19 | Method for preparing pyrano- [2,3-c] pyridine derivatives |
KR1020137003678A KR20130129902A (en) | 2010-07-20 | 2011-07-19 | Process for preparing pyrano-[2,3-c]pyridine derivatives |
SG2013004452A SG187146A1 (en) | 2010-07-20 | 2011-07-19 | Process for preparing pyrano - [2,3-c]pyridine derivatives |
EA201390016A EA201390016A1 (en) | 2010-07-20 | 2011-07-19 | METHOD FOR PRODUCING PIRANO DERIVATIVES [2,3-C] PYRIDINE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36588010P | 2010-07-20 | 2010-07-20 | |
US61/365,880 | 2010-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012012391A2 true WO2012012391A2 (en) | 2012-01-26 |
WO2012012391A3 WO2012012391A3 (en) | 2013-08-08 |
Family
ID=45497409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/044489 WO2012012391A2 (en) | 2010-07-20 | 2011-07-19 | Process for preparing pyrano - [2,3-c]pyridine derivatives |
Country Status (10)
Country | Link |
---|---|
US (1) | US8759523B2 (en) |
EP (1) | EP2595994B1 (en) |
JP (1) | JP5762538B2 (en) |
KR (1) | KR20130129902A (en) |
CN (1) | CN103492393A (en) |
BR (1) | BR112013001257A2 (en) |
EA (1) | EA201390016A1 (en) |
ES (1) | ES2574179T3 (en) |
SG (1) | SG187146A1 (en) |
WO (1) | WO2012012391A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016096686A1 (en) | 2014-12-17 | 2016-06-23 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds having broad spectrum of activity |
US10649266B2 (en) | 2016-06-24 | 2020-05-12 | Boe Technology Group Co., Ltd. | Liquid crystal display and display device |
CN112830933A (en) * | 2021-02-04 | 2021-05-25 | 康化(上海)新药研发有限公司 | Synthetic method of 3, 4-dihydro-2H-pyrano [2,3-b ] pyridine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8613786D0 (en) | 1986-06-06 | 1986-07-09 | Beecham Group Plc | Active compounds |
DE10120619A1 (en) * | 2001-04-26 | 2002-10-31 | Merck Patent Gmbh | 2- (5- (4-fluorophenyl) -3-pyridylmethylaminomethyl-chromane |
EP1442037A1 (en) * | 2001-11-09 | 2004-08-04 | PHARMACIA & UPJOHN COMPANY | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
AR042486A1 (en) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | QUINOLINE AND NAFTIRIDINE COMPOSITE HALOSUSTITUDED IN POSITION 3, PROCEDURE TO PREPARE THE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION. |
-
2011
- 2011-07-19 JP JP2013520798A patent/JP5762538B2/en active Active
- 2011-07-19 WO PCT/US2011/044489 patent/WO2012012391A2/en active Application Filing
- 2011-07-19 CN CN201180035535.7A patent/CN103492393A/en active Pending
- 2011-07-19 BR BR112013001257A patent/BR112013001257A2/en not_active Application Discontinuation
- 2011-07-19 EA EA201390016A patent/EA201390016A1/en unknown
- 2011-07-19 ES ES11810260.7T patent/ES2574179T3/en active Active
- 2011-07-19 SG SG2013004452A patent/SG187146A1/en unknown
- 2011-07-19 KR KR1020137003678A patent/KR20130129902A/en not_active Application Discontinuation
- 2011-07-19 EP EP11810260.7A patent/EP2595994B1/en active Active
- 2011-07-19 US US13/810,741 patent/US8759523B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of EP2595994A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016096686A1 (en) | 2014-12-17 | 2016-06-23 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds having broad spectrum of activity |
US10221144B2 (en) | 2014-12-17 | 2019-03-05 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds having broad spectrum of activity |
US10649266B2 (en) | 2016-06-24 | 2020-05-12 | Boe Technology Group Co., Ltd. | Liquid crystal display and display device |
CN112830933A (en) * | 2021-02-04 | 2021-05-25 | 康化(上海)新药研发有限公司 | Synthetic method of 3, 4-dihydro-2H-pyrano [2,3-b ] pyridine |
Also Published As
Publication number | Publication date |
---|---|
BR112013001257A2 (en) | 2016-05-17 |
EP2595994A4 (en) | 2014-12-10 |
EP2595994B1 (en) | 2016-04-20 |
SG187146A1 (en) | 2013-02-28 |
KR20130129902A (en) | 2013-11-29 |
US20130116436A1 (en) | 2013-05-09 |
CN103492393A (en) | 2014-01-01 |
US8759523B2 (en) | 2014-06-24 |
JP2013541498A (en) | 2013-11-14 |
ES2574179T3 (en) | 2016-06-15 |
EA201390016A1 (en) | 2013-09-30 |
JP5762538B2 (en) | 2015-08-12 |
EP2595994A2 (en) | 2013-05-29 |
WO2012012391A3 (en) | 2013-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013123240A1 (en) | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists | |
JP2013500958A5 (en) | ||
WO2012012391A2 (en) | Process for preparing pyrano - [2,3-c]pyridine derivatives | |
AU2016365535B2 (en) | Method for producing N-retinoylcysteic acid alkyl ester | |
Matsuyama et al. | Intramolecular cyclization of (. omega.-carboxyalkyl) sulfonium salts. A novel synthesis of macrocyclic lactones | |
Bucciarelli et al. | Regioselectivity of ring-opening reactions of optically active N-acetyl-2-methoxycarbonylaziridine | |
Thaima et al. | Progress toward the total synthesis of 9β-hydroxyvertine: Construction of an advanced quinolizidine intermediate | |
Ichikawa | Biomimetic synthesis of theonellin isocyanide | |
WO2002022618A1 (en) | Method for preparing camptothecin and its derivatives | |
AU2014222390A1 (en) | Method of preparing 2-((5Z,8Z,11 Z,14Z,17Z)-icosa-5,8,1 1,14,17-pentaenyloxy)butanoic acid | |
EP1853611A1 (en) | Recovery of cci-779 from mother liquors | |
FI72726C (en) | Process for preparing 5,6,7,7a-tetrahydro-4H-thieno (3,2-c) pyridin-2-one derivative. | |
CN109970620B (en) | Method for preparing saxagliptin intermediate | |
Hoffmann et al. | Total synthesis of mycinolide‐V | |
CN113666904A (en) | Preparation method of sitagliptin phosphate intermediate | |
US20080319231A1 (en) | Process for the Preparation of Alkyl Phosphinates | |
Field | Synthesis of 3'-N-methylbiotin | |
Clezy et al. | The chemistry of pyrrolic compounds. XXXIV. Vinylporphyrins from derivatives of 2'-hydroxyethylporphyrins | |
JP5627594B2 (en) | Process for preparing hydrocodone using superacid | |
SU584785A3 (en) | Method of preparing thieno(3,2,-c)pyrimidine derivatives or salts thereof | |
Brimble et al. | Synthesis of the insect feeding deterrent peramine via Michael addition of a pyrrole anion to a nitroalkene | |
Isbell et al. | Synthesis of δ-eicosanolactone and δ-docosanolactone directly from meadowfoam oil | |
EP3383832A1 (en) | Process for the preparation of 3-substituted cannabinoid compounds | |
US20050096475A1 (en) | Process for producing cyclic compound | |
EP4045671A1 (en) | Process of preparing (1r, 4r, 5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione(salinosporamide a; marizomib) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11810260 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 224193 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201390016 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13810741 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013520798 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011810260 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137003678 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013001257 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013001257 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130117 |